
Chinese pharmaceutical manufacturing company in Chengdu, Sichuan and a subsidiary of Chipscreen Biosciences, the Shenzhen based original innovative drug developer founded in 2001 and listed on the Shanghai STAR Market under code 688321. Produces the group's marketed original medicines, including the histone deacetylase inhibitor chidamide for peripheral T-cell lymphoma and breast cancer and the PPAR pan-agonist chiglitazar sodium for type two diabetes, and supports its pipeline built on a chemical genomics driven discovery platform.
Bewertung hinterlassen